Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Neurol. 2009 Nov;16(11):1230-2. doi: 10.1111/j.1468-1331.2009.02702.x. Epub 2009 Jun 15.

Screening for LRRK2 R1441 mutations in a cohort of PSP patients from Germany.

Author information

1
Department of Neurodegenerative diseases, Hertie Institute for clinical brain research, University of Tuebingen, Tuebingen, Germany.

Abstract

BACKGROUND AND PURPOSE:

Mutations in the leucine-rich repeat kinase gene (LRRK2) have been shown to be the most common genetic cause of both familial and sporadic Parkinson's disease. Patients harboring LRRK2 mutations develop late onset PD that in most cases cannot be clinically distinguished from idiopathic PD. Furthermore, LRRK2 mutations have been reported to result in a broad spectrum of neuropathological alterations including progressive supranuclear palsy (PSP)-like Tau pathology.

METHODS:

We screened a cohort of 88 clinically confirmed PSP patients for mutations in exon 31.

RESULTS:

We did not find any of the known mutations or any new variants.

CONCLUSIONS:

Thus, there is no evidence that mutations in exon 31 of LRRK2 are a major risk factor for PSP. Our study, however, cannot rule out that other genetic variations in LRRK2 may be associated with PSP.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center